RxDoctor Payments DataLook up a doctor →

Johanna Contreras

Advanced Heart Failure and Transplant Cardiology · New York, NYNPI 1528188190

Payments from drug & device makers

$1,379,382in general payments, 2019–2025

Across 1,556 payments — averaging $886.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Livanova USA, Inc.$247K
  • Boehringer Ingelheim International GmbH$211K
  • AstraZeneca$150K
  • Boehringer Ingelheim$79K
  • E.r. Squibb & Sons, L.L.C.$78K
  • Alnylam Pharmaceuticals Inc.$74K
  • plus $541K from 39 others
$1,858in research payments, 2019–2025

Across 4 payments — averaging $464.48 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Lexicon Pharmaceuticals, Inc.$2K
  • Medtronic$300

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Livanova USA, Inc.39$247,035
Boehringer Ingelheim International GmbH142$210,640
AstraZeneca117$150,214
Boehringer Ingelheim110$78,669
E.r. Squibb & Sons, L.L.C.25$77,871
Alnylam Pharmaceuticals Inc.95$73,986
Genentech, Inc.16$58,616
Lexicon Pharmaceuticals, Inc.61$57,172
Abbott222$54,305
Boehringer Ingelheim Pharma GmbH & Co.kg11$51,169
Novartis183$46,399
Esperion Therapeutics, Inc.42$34,170
Bayer33$33,538
Merck51$28,751
Amgen58$27,219
Lilly USA, LLC21$24,971
Cvrx, Inc.70$24,603
Novo Nordisk74$24,054
Endotronix, Inc.3$22,635
Novo Nordisk AS6$21,129
Bridgebio Pharma, Inc.35$12,288
Scpharmaceuticals Inc.15$5,214
Biotronik Inc.29$3,491
Eli Lilly1$2,375
Boston Scientific20$1,795
Pfizer8$1,630
Nuwellis, Inc.13$1,556
Abiomed5$640
Bardy Diagnostics, Inc.10$596
Siemens Medical Solutions USA, Inc.6$498
Impulse Dynamics (USA) Inc.3$470
Akcea Therapeutics, Inc.5$454
Medtronic(2 entities)4$317
Paragonix Technologies, Inc.4$232
Ancora Heart, Inc.2$160
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)5$113
Stereotaxis Inc1$95
Kiniksa Pharmaceuticals International, PLC3$95
Johnson & Johnson2$53
Philips North America LLC1$38
Braemar Manufacturing, LLC1$31
Sandoz1$30
Daiichi Sankyo Inc.1$23
Heartflow, Inc.1$23
Kiniksa Pharmaceuticals, Ltd.1$17

How this compares

$1,379,382 in reported general payments places this provider in the 95th percentile of 106 advanced heart failure and transplant cardiology providers in New York.

See all advanced heart failure and transplant cardiology providers in New York →

Medicare billing

Part B allowed, 2024
$65,271
Medicare patients
158
Services billed
540

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other advanced heart failure and transplant cardiology in New York

See the full list for New York →

Where these figures come from

Is this you, or does something look wrong? →